Clinical

Dataset Information

0

A phase I/II study of Cetuximab combined with irinotecan and S-1 as first line therapy in metastatic colorectal cancer patients with KRAS wild type


ABSTRACT: Interventions: Cetuximab; bi-weekly administration 500mg/m2. Irinitecan is administered as an intravenous infusion at a dose of 120mg/m2 on day 1 and 15. And TS-1 is orally administered on days 1-14 of a 28-day cycle. Administration dose of TS-1 is based BSA : BSA<1.25m2, 40mg twice daily; 1.25-1.5m2, 50mg twice daily; >1.5m2, 60mg twice daily. Primary outcome(s): Phase I study To evaluate feasibility Phase II study Response rate Study Design: Single arm Non-randomized

DISEASE(S): Advanced Colorectal Cancer

PROVIDER: 2619853 | ecrin-mdr-crc |

REPOSITORIES: ECRIN MDR

Similar Datasets

| 2620142 | ecrin-mdr-crc
| 2620657 | ecrin-mdr-crc
| 2643378 | ecrin-mdr-crc
| 2620325 | ecrin-mdr-crc
| 2622245 | ecrin-mdr-crc
| 2621031 | ecrin-mdr-crc
2007-11-13 | E-GEOD-5562 | biostudies-arrayexpress
2020-12-21 | GSE158713 | GEO
| 2577537 | ecrin-mdr-crc
2023-11-21 | PXD040451 | Pride